Abstract:Molecularly directed targeted therapies have become a key component of caring for patients with metastatic solid tumors, both alongside and instead of conventional chemotherapy and immunotherapy. Treatment options for patients with advanced cancer have expanded dramatically over the past decade, with the development of a wide variety of targeted therapies for oncogene-addicted tumors and the demonstration of efficacy of immune checkpoint inhibitors for many cancer types. Cell-free circulating tumor DNA (ctDNA) is shed by tumor cells into the systemic circulation and, thanks to advancements in next-generation sequencing (NGS) technologies, affords the opportunity to noninvasively detect cancer-specific somatic variants. The use of ctDNA-based molecular genotyping for tumor profiling and identification of patients eligible for targeted therapies has been integrated into clinical practice for a variety of tumor types. The prime example of this is in non–small cell lung cancer (NSCLC), where identifying actionable variants via genomic profiling is essential to determining the appropriate standard of care for patients. The National Comprehensive Cancer Network recommends that all patients with metastatic NSCLC undergo molecular genotyping, and the European Society for Medical Oncology mandates testing for oncogenic drivers for which there are approved drugs. 1 ,2 Earlier approaches supported by the International Association for the Study of Lung Cancer prioritized tissue-based NGS at time of diagnosis, with ctDNA-based molecular genotyping relegated to the identification of resistance variants after progression on targeted therapy. 3 However, practical considerations, including faster resulting time, lower potential for sample inadequacy, and elimination of the need for invasive and, in some situations, prohibitively hazardous tissue sampling have led to the increased utilization of ctDNA molecular genotyping at diagnosis. 2 ,4 -6 Iams et al 6 report on a large, multi-institutional cohort evaluating the utility of a concurrent ctDNA-based and tissue-based molecular genotyping approach in a patient population with various metastatic cancers. The cohort consisted of 3209 patients with stage IV cancer: 1302 (41%) with NSCLC, 923 (29%) with colorectal cancer, 660 (20%) with breast cancer, and 324 (10%) with prostate cancer. Among 1448 patients found to have at least 1 actionable variant on tissue-based or ctDNA-based molecular genotyping, 135 (9.3%) had clinically actionable variants identified only in ctDNA testing. 6 This study has important implications and helps to solidify the added value of ctDNA-based molecular genotyping in identifying targetable variants that may not be recognized in tissue-only assessment. This finding highlights the utility of ctDNA-based genotyping in cases of intratumoral heterogeneity, as well as heterogeneity between a primary lesion and metastatic sites and can inform therapy selection. This study raises important practical questions. How should these results inform clinical practice? Should we use concurrent molecular genotyping across all solid tumors, and, if so, should testing be performed upon initial diagnosis, or at the time of progression? At present, the most substantial data supporting the use of concurrent ctDNA-based molecular genotyping to uncover actionable targets lies in NSCLC. Current NSCLC guidelines support the use of concurrent testing at time of initial diagnosis to decrease turnaround time and increase detection of targetable variants. 2 In addition, both the National Comprehensive Cancer Network and the European Society for Medical Oncology support the use of ctDNA testing at the time of diagnosis in specific clinical scenarios, including if patients are not fit to undergo invasive tissue sampling or when samples are inadequate for molecular analysis. Guidelines also support ctDNA molecular genotyping if initial tissue-based testing does not completely assess all recommended biomarkers due to tissue quantity or available testing methods. However, this recommendation includes the caveat that a repeat tissue-based analysis may be required if an oncogenic driver is not found. 1 ,2 Although the results presented by Iams et al 6 validate previously published findings in patients with metastatic NSCLC and support the use of concurrent ctDNA molecular genotyping in this population, open questions remain about how to translate these findings to other solid tumor types. In the subgroup of patients with breast cancer, 20.2% of actionable variants were uniquely identified by ctDNA-based molecular genotyping, with the majority consisting of ESR1 variants for which there was less than 50% tissue and ctDNA profiling based concordance. 6 On the basis of these results, for patients with breast -Abstract Truncated-

Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies

Abstract PO4-10-12: Value of Molecular Targets and Genome-Targeted Therapies FDA-Approved for Metastatic Breast Cancer, 2006-2023

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer

Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets

Abstract B005: Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board

Comprehensive genomic profiling in solid tumors: Enhancing treatment selection and prognosis.

Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board

Genomics to select treatment for patients with metastatic breast cancer

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes

NGS panels' capture of biomarkers associated with targeted therapies in clinical trials.

Druggable genomic landscapes of high-grade gliomas

Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution

Concurrent ctDNA and Tissue Genotyping

Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology

Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer

Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.